Dr. Karan's GLP-1 'forever' claims, fact-checked

What did @dr.karanr actually say?

The short version: stopping GLP-1 medications means the weight comes back, and that is not a drug failure, it is just how obesity works. Dr. Karan cited an analysis of over 9,000 people showing an average regain of 0.8 kg per month after stopping, with most people returning to baseline weight within about 1.5 years. He compared GLP-1s to blood pressure pills and statins, arguing the effect disappears when you stop the drug. He closed with a tiered analogy borrowed from eczema management, suggesting some people may eventually manage without medication, others occasionally, and some indefinitely.

Overall, this is a responsible take. He did not promise a cure, he did not downplay obesity biology, and he pushed back against the idea that stopping a GLP-1 is a personal failure. That framing matters in a space full of before-and-after grifts.

Does the science back this up?

Largely, yes. The weight regain data is real and well-documented. The 0.8 kg per month figure tracks closely with published withdrawal data from semaglutide trials.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed participants who stopped semaglutide 2.4 mg after 68 weeks. By one year post-discontinuation, two-thirds of the weight lost had been regained. A pooled analysis from the SURMOUNT trials on tirzepatide (Jastreboff et al., 2022, NEJM) showed similar patterns when the drug was stopped. The 9,000-person figure Dr. Karan references likely reflects a meta-analysis or pooled dataset drawing from these and related trials, though he does not name the specific paper, which is worth noting.

His framing of obesity as a "chronic relapsing condition" is consistent with how major clinical bodies, including the American Association of Clinical Endocrinology and the European Association for the Study of Obesity, now classify it. The statin comparison is a reasonable analogy, not a perfect one, but mechanistically defensible.

What did they get wrong (or right)?

More right than wrong, with one gap worth flagging. The eczema analogy is genuinely useful for public communication and avoids the trap of saying everyone needs lifetime treatment. Credit where it is due.

What is missing is nuance around who can successfully discontinue. Research suggests that patients who build significant lean muscle mass, improve insulin sensitivity, and change dietary behavior during their GLP-1 period may have a better trajectory after stopping than those who do not. A 2023 analysis in Obesity Reviews (Sumithran et al.) pointed to lifestyle co-interventions as a meaningful modifier of post-discontinuation outcomes, not a guarantee, but a real variable. Dr. Karan gestures at this when he lists "lifestyle changes are non-negotiable," but he treats it more as a moral footnote than a clinical lever that can actually shift the odds. That undersells the evidence.

He also does not mention that some people stop GLP-1s due to cost, side effects, or access rather than choice, and the regain data applies equally to involuntary discontinuation. That context is relevant for his audience.

What should you actually know?

Weight regain after stopping GLP-1 therapy is the expected biological outcome, not an exception. Planning for it is part of responsible prescribing, and any clinician or platform not discussing this upfront is doing patients a disservice.

The honest conversation involves three things. First, what is your goal: a defined period of treatment to shift metabolic risk, or long-term maintenance? Second, what are you building during treatment? Muscle mass, sleep quality, and dietary habits are not just wellness add-ons. They are the closest thing to a hedge against regain that the current evidence supports. Third, what is your exit plan, if you have one? Tapering versus abrupt discontinuation, monitoring, and follow-up are not standardized across prescribers right now, and that is a real gap in practice.

GLP-1 medications are not cures for obesity. They are effective pharmacological tools that work while you use them. That is true of most chronic disease medications, and it is not a reason to avoid them. It is a reason to be clear-eyed going in.